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Abstract 
Osteoblast number and activity decreases with aging, contributing to the age-associated decline of bone 
mass, but the mechanisms underlying changes in osteoblast activity are not well understood. Here, we 
show that the age-associated bone loss critically depends on impairment of the ability of 
megakaryocytes (MKs) to support osteoblast proliferation. Co-culture of osteoblast precursors with 
young MKs is known to increase osteoblast proliferation and bone formation. However, co-culture of 
osteoblast precursors with aged MKs resulted in significantly fewer osteoblasts compared to co-culture 
with young MKs, and this was associated with the downregulation of transforming growth factor beta. In 
addition, the ability of MKs to increase bone mass was attenuated during aging as transplantation of 
GATA1low/low hematopoietic donor cells (which have elevated MKs/MK precursors) from young mice 
resulted in an increase in bone mass of recipient mice compared to transplantation of young wild-type 
donor cells, whereas transplantation of GATA1low/low donor cells from old mice failed to enhance bone 
mass in recipient mice compared to transplantation of old wild-type donor cells. These findings suggest 
that the preservation or restoration of the MK-mediated induction of osteoblast proliferation 
during aging may hold the potential to prevent age-associated bone loss and resulting fractures. 
1. Introduction
The traditional view regarding the regulation of bone modeling/remodeling focuses on the cells involved 
directly with bone formation (osteoblasts) and resorption (osteoclasts), and how the actions of these 
cells regulate the reciprocal process. [1, 2]. Not surprisingly, much of the research on the effects of aging 
on bone health (e.g. senile osteoporosis) focuses on molecules directly involved in osteoblast-to-
osteoclast or osteoclast-to-osteoblast signaling [3, 4]. However, studies in animals have shed light on the 
role of other cells within the bone environment (e.g. endothelial cells, B-lymphocytes, MKs, etc.) in 
regulating the activity of osteoblasts and osteoclasts [5-8]. One cell type of particular interest is the MK, 
which plays a role in the regulation of bone formation and bone resorption within the marrow cavity [7-
21].  
Numerous mouse models have been made where MK numbers are increased. These mice also have 
greatly increased bone growth within the marrow cavity [9, 10, 20-27]. Importantly, osteosclerosis has 
been documented in patients with megakaryocytoses [28, 29]. Additional studies have shown that MKs 
have direct effects on osteoblast proliferation through direct cell-to-cell contact [7, 12, 13, 16-18] and 
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the inhibition of osteoclastogenesis, which is contact independent [8, 16, 19]. At least one critical aspect 
of the function of MKs is the formation and remodeling of the hematopoietic stem cell niche [9, 15, 30]. 
Aging results in a striking loss of cancellous bone within the marrow cavity and on the endosteal surface 
of cortical bone, which is known to be caused by an increase in osteoclast activity that outpaces the 
ability of osteoblasts to replace the lost bone [31, 32]. What is not known is whether the loss of steady 
state MK activity in bone cell regulation changes during aging. A better understanding of the role of MKs 
in the regulation of bone mass, and how this role changes with aging, could lead to the identification of 
novel therapies for osteoporosis that are able to both increase osteoblast activity and inhibit osteoclast 
activity indirectly by targeting the MK.  
To better understand MK regulation of bone cell activity during aging, we used a combination of in vitro 
experiments with osteoblasts and MKs derived from old or young mice. We observed reduced ability of 
old MKs to increase osteoblast proliferation, as well as a reduced response of old osteoblasts to the 
stimulatory effects of MKs. We then compared the ability of wild-type and megakaryocytotic 
hematopoietic progenitors (GATA1low/low) from young and old mice to increase bone mass in an adoptive 
transfer model. While young GATA1low/low cells increased bone mass in recipient mice compared to wild-
type cells, there were no differences observed in the bone mass of recipients of old GATA1low/low cells vs. 
old wild-type cells, suggesting that even when MKs were increased, their ability to regulate bone cell 
function was diminished with age. 
2. Materials and Methods  
2.1 Animals 
C57BL/6J and GATA1low/low mice were used in this study. Generation and breeding of mutant mice with 
selective loss of MK-expressed GATA1 were described previously [22, 33]. These mice have been 
backcrossed more than 16 generations, have been maintained on the C57BL/6 background, and were 
kindly provided by Dr. Stuart Orkin. C57BL/6 and GATA-1low/low mice were bred and housed in the animal 
facility at the Indiana University School of Medicine. All animal procedures were in compliance with 
protocols approved by the Institutional Animal Care and Use Committee at the Indiana University School 
of Medicine and were in compliance with the National Institutes of Health guide on the care and use of 
laboratory animals. 
2.2 Adoptive Transfer Studies 
For transplantation studies, recipient C57BL/6 mice received 1,100cGy ionizing radiation from a cesium 
source (split dose, both at 550cGy, 4 hours apart) and donor cells (106 spleen cells isolated from young 
GATA-1low/low or C57BL/6 wild-type mice were resuspended in 100 µl 1X phosphate buffered saline) were 
injected retro-orbitally within 2-3 hours after the second dose. Mice were monitored daily for signs of 
morbidity and mortality. Mice were euthanized 8 weeks post-transplantation.  
2.3 Complete Blood Count 
Mice were tail-bled and blood was analyzed for complete blood count (CBC) values using a validated 
HEMAVET® 950FS Hematology System (Drew Scientific, Waterbury, CT) at least 10 min after collection, 
but within 24 hours, as previously described [34, 35].  
2.4 Megakaryocyte Generation, Isolation, and Conditioned Media 
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Murine fetal liver derived MKs were prepared as previously described [19, 21]. In brief, fetuses were 
dissected from pregnant C57BL/6 mice at E13–15. The livers were removed and single cell suspensions 
made by forcing cells through an 18 g needle in complete media: Dulbecco Modified Eagle Medium 
(DMEM; 12100; Gibco, Dublin, Ireland) containing 5% fetal bovine serum (FBS Hyclone; GE Healthcare 
Life Sciences, Pittsburgh, PA) and 1,000 U/mL Penicillin/Streptomycin (Invitrogen, Waltham, MA). Young 
(3-4 mo) and old (22-24 mo) adult spleen derived MKs were prepared by mechanical digestion of the 
spleens by crushing the tissue. The cells were filtered and pelleted by centrifugation (500 xg for 6 min) 
and the pellet was resuspended in fresh complete DMEM containing 1% murine thrombopoietin (TPO) 
conditioned media [19, 27]. 
After 3–5 days for fetal liver MKs or 7-10 days for adult spleen MKs, MKs cells were enriched by 
separating them from the lymphocytes and other cells using a one-step albumin gradient to obtain an 
approximately 95% pure MK population [36]. The bottom layer of the gradient was 3% albumin in PBS 
(Bovine Albumin, protease free, fatty acid poor, Serologicals Proteins Inc., Kankakee, IL), the middle 
layer was 1.5% albumin in PBS, and the top layer was alpha minimum essential media (αMEM; 12000-
063; Gibco, Dublin, Ireland) containing the cells to be separated. The MK fraction was collected from the 
bottom of the tube and live cells were counted using trypan blue exclusion and a hemocytometer. 
2.5 RNA preparation and Real time PCR 
Total RNA was isolated with RNeasy Mini Kit (Qiagen, Venlo, Netherlands) and cDNA was synthesized 
using High Capacity cDNA Reverse Transcription Kits (Applied Biosystems, Foster City, CA) with total RNA 
(1 µg). Quantitative real-time PCR was performed according to the instructions provided for the 
StepOnePlus system (Applied Biosystems, Foster City, CA) with the SYBR Green PCR Mater Mix assay 
(Applied Biosystems, Foster City, CA). The amplification reaction was performed for 40 cycles with 
denaturation at 95 °C for 10 min, followed by annealing at 95 °C for 15 s and extension and detection at 
60 °C for 1 min. All reactions were run in triplicate. Primers were as follows: For Gapdh Fwd 5’-
CTTTGGCATTGTGGAAGGGC-3’; Rev 5’-CAGGGATGATGTTCTGGGCA-3’, for Tgfb1 Fwd 5’- 
TACGTCAGACATTCGGGAAGCAG-3’; Rev 5’- AAAGACAGCCACTCAGGCGTATC-3’, for Bmp2 Fwd 5’-
TGAGGATTAGCAGGTCTTTG-3’; Rev 5’-CACAACCATGTCCTGATAA-3’ 
 
2.6 Bone Cell Preparation and Isolation 
Neonatal murine calvarial osteoblast cells were prepared as previously described [37] from C57BL/6 
mice. Our technique was a modification of the basic method described by Wong and Cohn [38]. Briefly, 
calvaria were dissected from neonatal mice and then incubated with 4 mM EDTA in PBS for 10 min with 
gentle shaking at 37 °C. The EDTA solution was removed by vacuum and this step was repeated an 
additional time. Calvaria were then subjected to sequential collagenase-II digestions (200 U/mL; 
Worthington Biochemical Corporation, Lakewood, NJ) at 37 °C with gentle shaking. Fractions 1 and 2 
were from 10 min incubations and were discarded. Fractions 3-5 were from 15 min incubations and 
were pooled after passing the solution through a 100 µm filter to remove debris. A PBS wash of the 
calvaria was also performed between each incubation and these fractions were added to the pooled 
calvarial cells (CCs). This protocol results in ~90-95% osteoblast or osteoblast precursors based on 
previously reported criteria [37, 39, 40]. The same method was used to isolate adult bone cells from 
femurs and tibias, but with an additional step of first flushing the bones using PBS to remove the bone 
marrow. 
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2.7 Megakaryocyte and Bone Cell Co-Culture 
Bone cells and MKs were co-cultured by adding freshly isolated bone cells with freshly isolated MKs in a 
2:1 ratio. For CCs co-cultured with young vs. old adult spleen derived MKs, the cells were plated at 
80,000 live CCs ± 40,000 live MKs per well in a 6-well plate. For old vs. young adult bone cells co-cultured 
with fetal liver MKs, the cells were plated at 10,000 live bone cells ± 5,000 live MKs per well in a 96-well 
plate. It should be noted that fetal liver derived MKs were used when possible as they are an enriched 
source of MKs. After 5 days, the wells were washed 4x with PBS to remove loosely adherent MKs, then 
the adherent cells were removed by trypsinization (0.25% trypsin in EDTA; 25200-056; Gibco, Dublin, 
Ireland), pelleted by centrifugation (500 x g for 6 minutes), resuspended in complete DMEM media, and 
live cells were counted by trypan blue exclusion and hemocytometer. Results are presented from 3 
separate experiments.  
2.8 Cell staining, flow cytometry, and cell sorting 
Cells were washed with stain wash (PBS, 1% bovine calf serum, and 1% penicillin/streptomycin) and 
stained for 15 minutes on ice. Freshly isolated bone marrow cells from the hind limbs were stained with 
CD41 antibody (APC-Cy7; Clone MWReg30; BioLegend, San Diego, CA) and analyzed for CD41+ (MKs) 
using the BD LSRFortessa (BD Biosciences, San Jose, CA).  
2.9 Micro-computed Tomography 
Right lower limbs were defleshed and fixed in 10% neutral buffered formalin for 72 h and stored in 70% 
ethanol at 4 °C. Whole femurs were imaged using a desktop SkyScan 1172 µCT imaging system (SkyScan, 
Kontich, Germany). Scans were acquired at 60kV using an 8 μm voxel size. The femoral trabecular 
volume of interest in the distal femur encompassed regions from 0.25-0.75 mm from the distal growth 
plate. Cortical and trabecular measurements from the midshaft were obtained from a 0.6 mm segment 
that was 45% of the distance proximal of the length of the diaphysis from the growth plate (diaphysis 
length = distance of femoral head - distance of growth plate). 
2.10 Statistics 
All experiments were performed with technical triplicates with a minimum of three biological replicates. 
Statistical tests were determined based upon the number and types of comparisons made and are 
mentioned in the corresponding figure legends. For statistical significance we used an α value = 0.05. 
3. Results 
3.1 Megakaryocyte Numbers were Elevated in Aged Bone Marrow in C56BL/6 Mice 
Due to the positive role that MKs have on bone mass in mouse models with high MK numbers, we 
determined if age-related bone loss might be correlated with a decrease in bone marrow MKs. To do 
this, we compared the relative number of CD41+ MKs in the bone marrow of young (3-4 mo), middle-
aged (11-14 mo), and old-aged (22-24 mo) C57BL/6 mice by flow cytometric analysis of CD41+ cells. 
Interestingly, we observed an increasing frequency of MKs in the bone marrow cavity with age that 
reached statistical significance by 24 mos compared to 3 mos (Figure 1A; 3.1-fold enrichment). 
Coincident with the increased MKs during aging, we observed significantly increased platelets in the 
blood of old compared to young animals (Figure 1B; +41.6%; p < 0.05). In order to determine whether 
MK progenitors from aged mice are sensitized to differentiate into MKs, spleen cell suspensions from 
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young or old mice were cultured with TPO (the main MK growth factor). Following BSA gradient 
isolation, we found significantly more MKs generated in vitro from old spleens, compared to young 
spleens (+144% per spleen; p < 0.05; Figure 1C), suggesting that the increased MKs in old animals may 
be due to enhanced megakaryopoiesis.  
 
 
Figure 1. The effect of aging on megakaryocyte formation. Young (3-4 mo), middle-aged (11-14 mo), 
and old-aged (22-24 mo) C57BL/6 mice were characterized for MK phenotype. (A) Frequency of total 
bone marrow cells that stain positive for the MK marker CD41 by FACS analysis (n = 3 mice per age 
cohort). (B) Circulating platelet counts from whole blood (n = 21-31 mice per age cohort). (C) Total 
number of MKs generated per spleen from young or old spleens cultured in the presence of TPO and 
isolated by BSA gradient (n = 4 independent experiments). Data are expressed as means ± S.E.M. 
Kruskal-Wallis test with Dunn’s post hoc analysis (A), 1-Way ANOVA with Holm-Sidak post hoc analysis 
(B), and Unpaired t-test (C). * p < 0.05. MK = megakaryocyte.   
 
3.2 Aging Negatively Impacts the Ability of MKs to Stimulate the Proliferation of Osteoblasts  
Because we did not see a decrease in MKs during aging and osteoblast activity is known to be decreased 
in old mice, this suggested that old MKs are either inferior at stimulating osteoblasts, or that old 
osteoblasts are less able to respond to MK stimulation of bone formation. To test these hypotheses, we 
used a variety of in vitro co-culture experiments (Figure 2). First, we took cultured MKs derived from 
either young (3-4 mo) or old (22-24 mo) mice and co-cultured them with neonatal calvarial bone cells. 
As can be seen in Figure 2A, while old MKs trended toward increasing bone cell numbers (2.9-fold 
increase; p = 0.1422), young MKs had a stronger effect (10.1-fold increase; p < 0.001). To identify 
whether two MK secreted pro-osteoblastic growth factors, TGFβ1 and BMP2 [41], were changed in old 
MKs, we compared their expression by qPCR (Figure 2B). Our results showed that there was a strongly 
significant downregulation of Tgfb1 mRNA levels in MKs from old compared to young mice. To address 
whether old osteoblasts might be less responsive than young osteoblasts to MK stimulation, we co-
cultured bone cells derived from the long bones of young and old mice with young MKs. As shown in 
Figure 2C, there was a significant increase in young bone cell number in the presence of MKs (9.9-fold 
increase; p < 0.01), whereas the old bone cells did not appreciably change in the presence of MKs. Taken 
together these results suggest that the ability of bone cells to proliferate in response to MK stimulation 
is decreased in aging.  
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Figure 2. Megakaryocytes from aged mice are ineffective at stimulating bone cell proliferation. (A) 
MKs derived from young (3 mo) or old-aged (24 mo) mice were co-cultured (1:2 ratio) for 5 days with 
calvarial cells isolated from newborn pups by collagenase digestion. Results are from 6 separate 
experiments and normalized to within experiment CC only cell counts. (B) mRNA was isolated from 
lysates of MKs derived from young or old mice, reverse transcribed, and analyzed by qPCR. Gapdh was 
used as a normalization control. (n = 4-6) (C) Long bone cells were isolated by collagenase digestion from 
young or old-aged mice and co-cultured (10,000 cells per well) for 5 days with fetal-liver derived MKs 
(5,000 cells per well). (n = 3 mice per age group). Data are expressed as means ± S.E.M. Kruskal-Wallis 
with Dunn’s post hoc analysis (A), Student’s T-test (B), or 2-Way ANOVA with Holm-Sidak post hoc 
analysis (C). ** p < 0.01; *** p < 0.001. CC = calvarial cell. MK = megakaryocyte.  
3.3 Adoptive Transfer of Aged GATA1low/low Cells Failed to Recapitulate High Bone Mass Phenotype 
GATA1 is a transcription factor that critically regulates the development of both MKs and erythrocytes. 
Mice with a mutation in a GATA1 enhancer (GATA1low/low) that drives GATA1 expression in MKs, but not 
erythrocytes, show an overabundance of immature MKs and osteosclerosis, coupled with reduced 
platelets (due to immaturity of MKs) and increased spleen mass (due to marrow overcrowding causing 
extramedullary hematopoiesis) [21, 22].  
Notably, Vannuchi et al (2002) previously characterized many of the hematopoietic cell populations 
contained within the spleen of young and old wild-type and GATA-1low/low mice [43]. Of interest for this 
study, their data show that MK progenitors increase with age irrespective of genotype, but that GATA-
1low/low spleens contain higher numbers of MK/MK progenitors than wild-type mice of the same age. 
Supplementary Figure 1 provides additional information regarding the hematopoietic and MK/MK 
progenitor composition of the C57BL/6 and GATA-1low/low spleen cells. We confirm that there is an age-
associated increase in MK/MK progenitors contained within C57BL/6 spleens, and that GATA-1low/low 
spleen cells contain high numbers of MKs/MK progenitors. Importantly, as detailed in Supplementary 
Figure 1C&D, the number of hematopoietic stem cells (HSCs) within the spleens of young and old 
C57BL/6 and young GATA-1low/low mice is unlikely high enough to support stem cell-based hematopoiesis. 
Therefore, most likely our data were derived from progenitor activity. 
Previously we showed that the MK, spleen, and bone mass phenotypes of GATA1low/low mice could be 
adoptively transferred to wild-type mice following irradiation and transplantation with young spleen 
derived hematopoietic progenitors [42]. We used this model to test whether the ability of GATA1low/low 
cells to enhance bone mass changes with age. 
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If old MKs lose the ability to enhance bone mass, then we would not expect that adoptive transfer of old 
(18 mo) GATA1low/low hematopoietic progenitors to differ from the transfer of old wild-type 
hematopoietic progenitors. As expected, when hematopoietic progenitors were adoptively transferred 
from young (3 mo) GATA1low/low mice into young (3 mo) C57BL/6 mice (recipient mice), there was a 
significantly higher bone volume fraction of trabecular bone in the distal femur (BV/TV; +150%; Figure 
3A,B) when compared to adoptive transfer of young wild-type C57BL/6 hematopoietic progenitors. This 
change was primarily driven by a greater number of trabeculae (Tb.N; +120%; Table 1). We also 
observed the presence of trabecular bone in the midshaft of mice receiving the young GATA1low/low cells, 
which is a characteristic trait of this mutation (Figure 3C,D). Consistent with a loss of the ability of old 
MKs to enhance bone mass, we did not observe any differences between C57BL/6 mice receiving old 
GATA1low/low mutant or old wild-type cells (Figure 3 and Table 1). Unlike young mutant cells, old 
GATA1low/low cells failed to induce midshaft trabecular bone accumulation (Figure 3C,D and Table 1). To 
verify that the adoptive transfer of the old GATA1low/low cells indeed worked, we also compared spleen 
weight and platelet counts (Figure 3E,F). Indeed adoptive transfer of GATA1low/low cells significantly 
increased spleen mass for both young (+124%; p < 0.001) and old (+37%; p < 0.05) cells when compared 
to adoptive transfer of wild-type cells. There were also significantly fewer circulating platelets in mice 
that received either young (-75%; p < 0.001) or old (-90%; p < 0.001) GATA1low/low cells. 
3.4 Adoptive Transfer of Aged Hematopoietic Cells Results in Cortical Expansion at the Femoral Midshaft 
and Increased Trabecular Bone Fraction in the Distal Femur 
Interestingly, adoptive transfer with old hematopoietic cells resulted in a significant increase in cortical 
expansion compared to that observed with young spleen cells, independent of genotype. Specifically, as 
detailed in Table 1, transplantation of old wild-type cells significantly increased cortical tissue area (T.Ar; 
+31%; p < 0.001), bone area (B.Ar; +22%; p < 0.001), and marrow area (M.Ar; +37%; p < 0.001) 
compared to that observed with transplantation of young wild-type cells. Likewise, transplantation of 
old GATA1low/low hematopoietic cells significantly increased cortical tissue area (T.Ar; +26%; p < 0.001), 
bone area (B.Ar; +21%; p < 0.001), and marrow area (M.Ar; +32%; p < 0.001) compared to that observed 
with transplantation of young GATA1low/low cells. 
With regard to trabecular bone parameters (Table 1), transplantation of old wild-type cells were better 
than young wild-type cells at increasing trabecular bone fraction (BV/TV; +129%; p < 0.001). This 
appears to be a result of old wild-type cells increasing trabecular thickness (Tb.Th; +35%; p < 0.001) and 
number (Tb.N; +66%; p < 0.001), and a decrease in trabecular spacing (Tb.Sp; -9%; p=0.002). As noted 
above, the transplantation of old GATA1low/low cells resulted in a trabecular bone phenotype which was 
not different from that of transplantation of old wild-type cells.  
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Table 1. Bone mass parameters as measured by µCT in recipient mice following 8wk adoptive 
transfer of young or old, wild-type or GATA1
low/low
 hematopoietic cells
a
 
  Young Donors Old Donors 
Variables comparedb Wild-type GATA1low/low Wild-type GATA1low/low 
Distal trabecular         
BV/TV (%) 3.53 ± 0.31 8.67 ± 1.34*** 8.10 ± 0.71 7.34 ± 1.01 
Tb.Th (mm) 0.051 ± 0.001 0.055 ± 0.001 0.069 ± 0.002 0.070 ± 0.005 
Tb.Sp (mm) 0.336 ± 0.007 0.318 ± 0.021 0.306 ± 0.005 0.328 ± 0.013 
Tb.N (mm-1) 0.693 ± 0.055 1.541 ± 0.227*** 1.148 ± 0.073 1.006 ± 0.093 
Conn.D (µm-3) 0.020 ± 0.002 0.110 ± 0.023*** 0.030 ± 0.003 0.030 ± 0.004 
Midshaft trabecular         
BV/TV (%) 0.02 ± 0.01 7.00 ± 2.57*** 0.35 ± 0.14 0.79 ± 0.43 
Tb.Th (mm) 0.013 ± 0.003 0.051 ± 0.007*** 0.041 ± 0.007 0.053 ± 0.007 
Tb.Sp (mm) 0.475 ± 0.002 0.415 ± 0.030 0.730 ± 0.011 0.754 ± 0.022 
Tb.N (mm-1) 0.008 ± 0.004 1.083 ± 0.420*** 0.061 ± 0.017 0.107 ± 0.044 
Midshaft cortical         
Diaphysis length 
(mm) 12.41 ± 0.07 12.27 ± 0.04 13.62 ± 0.13 13.68 ± 0.09 
T.Ar (mm2) 1.57 ± 0.02 1.59 ± 0.02 2.05 ± 0.05 2.01 ± 0.07 
B.Ar (mm2) 0.73 ± 0.01 0.71 ± 0.04 0.89 ± 0.02 0.86 ± 0.03 
B.Ar/T.Ar (%) 46.5 ± 0.4 45.2 ± 2.1 43.8 ± 0.8 42.9 ± 1.0 
M.Ar (mm2) 0.84 ± 0.01 0.88 ± 0.05 1.15 ± 0.04 1.16 ± 0.05 
Ct.Th (mm) 0.17 ± 0.01 0.17 ± 0.01 0.18 ± 0.01 0.17 ± 0.01 
MMI polar (mm4) 0.29 ± 0.01 0.28 ± 0.02 0.49 ± 0.02 0.46 ± 0.03 
a Values are expressed as mean ± S.E.M. (n = 10-13). Bolded values represent statistically significant 
differences following 2-way ANOVAs and Holm-Sidak post-hoc analysis. Comparisons were between 
age-matched wild-type and mutant parameters. (*** p < 0.001). 
b BV/TV = bone volume / total volume; Tb.Th = trabecular thickness; Tb.Sp = trabecular spacing; Tb.N = 
trabecular number; Conn.D = connectivity density; T.Ar = tissue area; B.Ar = bone area; M.Ar = marrow 
area; Ct.Th = cross-sectional thickness; MMI = mean moment of inertia. 
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Figure 3. Adoptive transfer of young, but not old megakaryocyte skewed hematopoietic cells, 
increased bone mass in young wild-type recipient mice. Young C57BL/6 male mice were lethally 
irradiated and transplanted with young (3 mo) or old (18 mo) wild-type or GATA1low/low spleen cells by 
retro-orbital injection. Adoptively transferred (recipient) mice were euthanized and analyzed for femoral 
bone phenotype by µCT after 8 weeks. (A) Representative 3D renderings of distal trabecular bone from 
each group. (B) µCT analyses of bone volume fraction (BV/TV) of distal trabecular region. (C) 
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Representative 3D renderings of midshaft cortical bone with trabecular bone highlighted in white. (D) 
µCT analyses of BV/TV of midshaft trabecular bone region. (E) Comparisons of spleen mass at sacrifice. 
(F) Platelet counts taken from whole blood at sacrifice. (B,D) Each data point represents a unique 
animal. Black bars indicate average of population. (E,F) Bars are averages with S.E.M. Two-way ANOVA 
with Holm-Sidak post-hoc analyses. * p < 0.05,*** p < 0.001. Tb = trabecular. 
4. Discussion 
The work outlined in this paper extends from our previous publications showing how MKs orchestrate 
increased bone mass through actions on osteoblasts [9, 12, 16-19]. To better understand how MKs 
might be involved with age-related bone loss, we sought to determine how the bone marrow MK 
population changes during aging, and what effect age has on the ability of MKs to alter osteoblast 
activities.  
To determine how aging affects the MK population, we assessed the frequency of MKs in the bone 
marrow of C57BL/6 mice. We observed an age-related increase in the frequency of MK cells in the bone 
marrow and an increase in the number of MKs generated from aged spleens in vitro (Figure 1). Further, 
as shown in Supplementary Figure 1 and as reported by Vannuchi et al (2002), spleens from old wild-
type and old GATA-1low/low mice contained more MK/MK progenitors than did genotype matched young 
mice [43]. While it is unclear whether the increased number of MKs was due to an increase in MK 
progenitors or an increased sensitivity to TPO, an age-associated skewing to the MK/erythrocyte 
progenitor (MEP) population has been observed in both humans and mice [43, 44]. 
We then explored the interaction between MKs and osteoblasts during aging by comparing both the 
ability of young and old MKs to stimulate osteoblast proliferation, as well as, by comparing the ability of 
young and old osteoblasts to respond to MKs. While old MKs trended toward reduced ability to 
stimulate the proliferation of osteoblasts, the most striking difference we observed was the inability of 
old osteoblasts to respond to MKs (Figure 2).  
MKs have been shown to produce TGF-β isoforms 1, 2, and 3 [41]. TGF-β is a major bone cytokine [45] 
and stimulates the proliferation of osteoblast progenitors, but inhibits their maturation [46]. Our data 
shown in Figure 2B demonstrate that TGF-β1 mRNA expression was markedly reduced in MKs derived 
from old mice. These data are consistent with those of Gazit et al (1998) showing that there is a 
decrease in TGF-β availability and signaling in bone from aged male mice. One of the co-receptors for 
TGF-β, TGFβR-1a was shown to be downregulated in aged osteoblasts [47], and old rat and human 
osteoblasts showed a lack of response to TGF-β [48, 49], which suggests that old osteoblasts may be less 
responsive to TGF-β from MKs. While these data demonstrate distinct differences with age, they do not 
conclusively demonstrate the role of MK-mediated TGF-β production in this process. Should future 
studies confirm this mechanism of action, increasing TGFβR-1a expression and/or activity or 
downstream TGFβR signaling in aged osteoblasts may serve as an important therapeutic approach to 
increasing bone mass in aged individuals. 
To confirm that aged MKs would have a reduced capacity to stimulate anabolic bone responses in vivo, 
we used the adoptive transfer model in which the hematopoietic cells of young C57BL/6 mice were 
replaced with either young or old GATA1low/low hematopoietic cells, and findings were compared to the 
bone phenotype of mice receiving age-matched wild-type cells (Figure 3 and Table 1). Consistent with a 
reduced ability to enhance bone mass, mice receiving spleen cells from old GATA1low/low donors showed 
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no enhancement of trabecular bone in either the distal femur or cortical midshaft. This is in stark 
contrast to the trabecular bone enhancement that was observed in mice receiving spleen cells from 
young GATA1low/low donors. Further, our in vitro results suggested that aging had a negative effect on 
both the ability of MKs to stimulate osteoblast cell counts as well as a reduced ability of osteoblasts to 
respond to MKs (Figure 2). While not proof of cause, taken together our data suggest that the increase 
in MK/MK progenitors seen in old C57BL/6 donors, young GATA-1low/low donors, and old GATA-1low/low 
donors compared to young C57BL/6 donors is responsible for the bone phenotype observed in recipient 
mice.   
Interestingly, adoptive transfer of old hematopoietic cells (irrespective of genotype), resulted in a 
significant increase in cortical expansion. This cortical expansion may be explained by transplantation of 
increased numbers of osteoclast progenitors (myeloid skewing with aging), resulting in increased 
numbers of osteoclasts forming in recipient mice. Additionally, adoptive transfer of old C57BL/6 
hematopoietic cells resulted in a significant increase in trabecular bone volume fraction compared to 
transfer of young C57BL/6 hematopoietic cells. The increase in trabecular bone volume fraction was 
likely due to an increase in both trabecular number and thickness, suggesting increased osteoblast 
activity. It is intriguing that transfer of old hematopoietic cells into young recipient mice results in 
striking changes in bone phenotype compared to transfer of young wild-type cells. Indeed, as 
inflammation is a well-documented aging phenomenon (“inflammaging”), it is possible that 
transplantation of any old hematopoietic cells into young mice could result in an initial stimulation of 
osteoblast activity, due to increased expression of numerous inflammatory cytokines. Alternatively, the 
increase in osteoclast progenitors in mice transplanted with old donor cells, could themselves stimulate 
the recipient osteoblast cells. Understanding the mechanisms responsible for the increased trabecular 
bone mass with transplantation of old donor cells, and whether the bone phenotype would persist over 
time, remains to be determined. 
In conclusion, we demonstrated that aging negatively affects the ability of MKs to enhance bone mass 
and that this was due to a reduction in MK-stimulated osteoblast proliferation. Because the age-related 
decline of bone mass is driven by osteoclastic bone resorption outpacing osteoblastic bone formation [1, 
2], the decline in the ability of MKs to orchestrate osteoblastic activity may be a contributing factor.  
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Highlights 
 
 Megakaryocytes and platelets increase with age but bone mass declines  
 Megakaryocyte increase of osteoblasts and bone formation declines with age 
 Aging decreases response of bone cells to megakaryocytes 
 Transplantation of old hematopoietic cells increases cortical bone expansion 
 Transplantation of old hematopoietic cells increase trabecular bone parameters 
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